$BLACKGOLD NATURAL RESOURCESLTD(41H.SI)$On Monday, Jilin Governor Han Jun said the northeastern province – which experiences very cold winters – would try to accelerate thermal coal imports from Russia, Indonesia and Mongolia.
$BLACKGOLD NATURAL RESOURCESLTD(41H.SI)$“Since the Australian coal ban, there has been a shortage of 35 million tonnes of high-quality coal. Currently, 70 per cent of [China’s] imported coal is from Indonesia, with an energy value of 3,800 kcal/kg, and it is difficult to import enough thermal coal with high calorific value and low sulphur,” said a note by Nanhua Futures on Tuesday.
$Greenidge Generation Holdings Inc.(GREE)$Trying to understand better:Excerpts from Sprt/Gree merger notice:As previously announced, the exchange ratio for the merger has been determined and Support.com shareholders will receive 0.115 shares of Greenidge Class A Common Stock for each share of Support.com Common Stock held prior to closing.For 20 Sprt shares, you get 2 GREE shares.Issue price $10.
$Greenidge Generation Holdings Inc.(GREE)$Correct me if i am wrong: Now conversion rate is changed to USD43.40, techincally the "mergered" investors need to be compensated for the price differences against their merger rates...Need professional advice on this[流泪] [流泪] [流泪] [流泪] [流泪]
$NRX Pharmaceuticals Inc.(NRXP)$Tamir Pardo, a former head of the Mossad, joined the board of directors of NeuroRX, which plans to bring Israel's BriLife COVID-19 vaccine to world market..No FDA approval maybe needed.
$NRX Pharmaceuticals Inc.(NRXP)$Excerpt from Dr. Jonathan Javitt, 1 hour ago.@Factchecker.In response to your concern, nobody has "sliced" any data. Today's report represents data for Respiratory Distress Index across all patients, all baseline severities, and all sites of care. No subgroups or covariates were reported. The prespecified endpoint reported today and submitted to FDA for review is clearly listed on https://clinicaltrials.gov/ct2/show/NCT04311697 under "Other Outcome Measures" and represents a physiologic measure of lung oxygenation, as distinct from the overall primary endpoints (also listed on clinicaltrials.gov) of "alive and free of respiratory failure at 60 days," "Survival at 60 days," and other measures of how patients survive and
$Vivos Therapeutics(VVOS)$The FDA approval for its OSA is worth only a $2.00 increments in share price... pathetically insult to their medical profession.. what is happening!!!